Wavelets Synchronous Spectrofluorimetric Determination of Remdesivir in the Presence of Its Alkaline-Induced Degradation Product

Fluorescence spectroscopy has lately emerged as a very promising analytical technique due to its exceptional sensitivity and environmentally friendly attributes. In pharmaceutical quality control, there is an increasing demand for analytical methods that are straightforward, swift, cost-effective, and able to deliver dependable results with high sample throughput. Remdesivir is a novel antiviral drug first formulated for the treatment of Ebola virus sickness. In 2020, the United States Food and Drug Administration (US-FDA) approved it for the treatment of COVID-19 infections caused by the SARS-CoV-2 virus. The primary objective of this study is to develop a sensitive, accurate, and exact wavelet synchronous spectrofluorimetric approach for the quantification of Remdesivir in bulk powder and pharmaceutical formulations, accounting for its alkaline-induced degradation product. The emission was documented at 248 nm following stimulation at 408 nm. The enhanced emission exhibited a strong linear association between wavelet synchronous fluorescence intensity and Remdesivir concentration, ranging from 100 to 1200 ng/ml, with a determination coefficient of 0.9997. The proposed approach was validated in accordance with ICH principles and was effectively utilized for the quantification of Remdesivir in bulk powder and pharmaceutical formulations, despite the presence of its alkaline-induced breakdown product.